Overview

Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model

Status:
Recruiting
Trial end date:
2023-03-17
Target enrollment:
Participant gender:
Summary
Study to assess the efficacy and safety of a multiple dose regimen and a single dose regimen of intranasal Neumifil, administered prior to challenge with Influenza virus in healthy adult participants
Phase:
Phase 2
Details
Lead Sponsor:
Pneumagen Ltd.